Literature DB >> 2324159

The tumor-inhibiting effect of diethylstilbestrol and its diphosphate on the Nb-H and Nb-R prostatic carcinomas of the rat.

M R Schneider1, A Humm, A H Graf.   

Abstract

For many years, diethylstilbestrol (DES) and its diphosphate (DESPP; Honvan) have been standard therapies for prostatic carcinoma. The effects of DES, its monophosphate (DESP) and of DESPP on the weights of accessory sex organs of mice and rats, and on the experimental Noble Nb-H and Nb-R prostatic carcinomas of the rat were, therefore, compared. In intact mature mice, all three compounds led to a strong and dose-dependent inhibition of seminal vesicle weights and testosterone levels, whereas only a slight antiandrogenic activity in castrated mice was found. In intact rats, DES, DESP and DESPP strongly inhibited accessory sex organ weights and testosterone levels. In castrated rats, however, no antiandrogenic activity was determinable. The prostate carcinoma-inhibiting effects of DES and DESPP were tested in comparison with castration in the transplantable hormone-sensitive Nb-H and Nb-R prostatic carcinoma in rats. Whereas castration caused only a retardation of tumor growth, DES and DESPP (3 x 0.1 mg/kg and 1.0 mg/kg weekly s.c.) led to an almost complete inhibition, which was significantly (P less than 0.01) better than the effect of castration. As the weights of accessory sex organs were identically reduced by either castration or the estrogens, a direct tumor-inhibiting effect of DES and DESPP in addition to their testosterone-lowering activity is obvious. This was proved in an experiment with castrated rats. The only slightly inhibitory activity of castration was strongly potentiated by concomitant administration of DES. Moreover, histological examinations revealed that Nb-H and Nb-R tumors were much more damaged by treatment with DES or DESPP than after castration. Morphometry of the tumors showed that tumor reduction is associated with a decrease in the ratio of the epithelial to the stromal density, i.e. there was an even more pronounced decrease in epithelial cells than that found by merely measuring tumor area. These studies show that the prostate carcinoma-inhibiting effect of DES and DESPP in the Nb model is superior to the effect of castration and that they act directly on the tumor cells used, even in castrated rats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324159     DOI: 10.1007/bf01612671

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  17 in total

1.  Chemotherapeutic and hormonal considerations of the Nb rat prostatic adenocarcinoma model.

Authors:  J R Drago; L B Goldman; M E Gershwin
Journal:  Prog Clin Biol Res       Date:  1980

2.  Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma.

Authors:  L Daehlin; A Bergh; J E Damber
Journal:  Urol Res       Date:  1987

3.  Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5 alpha-reductase.

Authors:  N Kadohama; M Wakisaka; U Kim; J P Karr; G P Murphy; A A Sandberg
Journal:  J Natl Cancer Inst       Date:  1985-02       Impact factor: 13.506

4.  Comparison of various hormonal therapies for prostatic carcinoma.

Authors:  J Geller; J D Albert
Journal:  Semin Oncol       Date:  1983-12       Impact factor: 4.929

5.  Antitumor activity of antiestrogenic phenylindoles on experimental prostate tumors.

Authors:  M R Schneider; E von Angerer; W Höhn; F Sinowatz
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

6.  Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Prostate       Date:  1983       Impact factor: 4.104

7.  The Nb rat prostatic adenocarcinoma model system.

Authors:  J R Drago; L B Goldman; R E Maurer
Journal:  Prog Clin Biol Res       Date:  1980

8.  Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells.

Authors:  P Schulz; H W Bauer; W P Brade; A Keller; F Fittler
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate.

Authors:  M R Schneider; E von Angerer; J Prekajac; W P Brade
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

10.  Antiestrogens do not counteract the inhibitory effect of estradiol-17 beta on the growth of the Dunning R3327 prostatic adenocarcinoma.

Authors:  M Landström; J E Damber; A Bergh; R Tomic; L Carlsson-Bostedt; T Stigbrand
Journal:  Prostate       Date:  1988       Impact factor: 4.104

View more
  7 in total

Review 1.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Dose/response study of the effects of oestrogens on tumour growth and morphology in the Dunning R3327 prostatic adenocarcinoma.

Authors:  M Landström; J E Damber; A Bergh; R Tomic
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.

Authors:  T Spruss; S Schertl; M R Schneider; R Gust; K Bauer; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Antitumour and immunological activity of a beta 1----3/1----6 glucan from Glomerella cingulata.

Authors:  K Gomaa; J Kraus; F Rosskopf; H Röper; G Franz
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Evaluation of the antitumour activity of coumarin in prostate cancer models.

Authors:  A Maucher; M Kager; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Antitumour activity of coumarin in prostate and mammary cancer models.

Authors:  E von Angerer; M Kager; A Maucher
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Effect of zindoxifene on experimental prostatic tumours of the rat.

Authors:  M R Schneider; C D Schiller; A Humm; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.